Because autophagy is a general-purpose degraded, our platform can degrade more than just proteins.
It can target protein aggregates, dysfunctional mitochondria, viruses, bacteria, and other cellular organelles.
TAU, BRD4, TPD43, SNCA, and mitochondria are our proof-of-concept targets. To begin with, Automera is developing assets against these targets to prove the range and efficacy of our platform.
Next, we will be going after a series of rare and genetic diseases, to further validate our platform against novel and hard-to-drug targets.If you have a hard-to-drug target, let’s work together degrade it.